Enliven Therapeutics Statistics
Share Statistics
Enliven Therapeutics has 48.86M shares outstanding. The number of shares has increased by 14.62% in one year.
| Shares Outstanding | 48.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.23M |
| Failed to Deliver (FTD) Shares | 149 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 6.91M, so 14.14% of the outstanding shares have been sold short.
| Short Interest | 6.91M |
| Short % of Shares Out | 14.14% |
| Short % of Float | 22.84% |
| Short Ratio (days to cover) | 21.89 |
Valuation Ratios
The PE ratio is -6.87 and the forward PE ratio is -11.46.
| PE Ratio | -6.87 |
| Forward PE | -11.46 |
| PS Ratio | 0 |
| Forward PS | 113597.6 |
| PB Ratio | 2 |
| P/FCF Ratio | -8.01 |
| PEG Ratio | n/a |
Enterprise Valuation
Enliven Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 10.28, with a Debt / Equity ratio of 0.
| Current Ratio | 10.28 |
| Quick Ratio | 10.28 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is -33.92%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | -33.92% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.56M |
| Employee Count | 46 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 95.38% in the last 52 weeks. The beta is 0.93, so Enliven Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | 95.38% |
| 50-Day Moving Average | 26.64 |
| 200-Day Moving Average | 22.61 |
| Relative Strength Index (RSI) | 38.67 |
| Average Volume (20 Days) | 259.97K |
Income Statement
In the last 12 months, Enliven Therapeutics had revenue of $0 and earned -$71.58M in profits. Earnings per share was $-2.01.
| Revenue | 0 |
| Gross Profit | -297.00K |
| Operating Income | -83.53M |
| Net Income | -71.58M |
| EBITDA | -81.93M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.01 |
Balance Sheet
The company has $100.14M in cash and $335.00K in debt, giving a net cash position of $99.81M.
| Cash & Cash Equivalents | 100.14M |
| Total Debt | 335.00K |
| Net Cash | 99.81M |
| Retained Earnings | -154.45M |
| Total Assets | 305.43M |
| Working Capital | 279.97M |
Cash Flow
In the last 12 months, operating cash flow was -$61.27M and capital expenditures -$149.00K, giving a free cash flow of -$61.42M.
| Operating Cash Flow | -61.27M |
| Capital Expenditures | -149.00K |
| Free Cash Flow | -61.42M |
| FCF Per Share | -1.73 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.65% |
| FCF Yield | -5.41% |
Analyst Forecast
The average price target for ELVN is $37, which is 59.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $37 |
| Price Target Difference | 59.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Feb 24, 2023. It was a backward split with a ratio of 1:4.
| Last Split Date | Feb 24, 2023 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 38.61 |
| Piotroski F-Score | 1 |